Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation, the Company's need for additional capital which may not be available in a timely manner or at all and which, if not obtained, will have a material adverse impact on the Company and its ability to continue; the impact of the global economic downturn and credit crisis which have negatively affected the availability and terms of debt and equity financings and may have a negative effect on our sales operations and research and development initiatives; uncertainty whether an Investigational New Drug application ("IND") or Clinical Trial application ("CTA") will be compiled or submitted for Topical Interferon Alpha-2b or L-DOS47 as currently planned or at all, or if submitted, whether the Company will be permitted to undertake human testing; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; uncertainty whether the planned Topical Interferon Alpha-2b Phase IIb / III clinical trials, the human pharmacokinetic study, the ongoing AGW clinical trial in Sweden and Germany, or the planned L-DOS47 clinical trial referred to in this news release will be approved or initiated, in the case of Topical Interferon Alpha-2b and L-DOS47, or will be completed as planned, within the time frames expected by the Company, or at all or will achieve expected results; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, including the possibility that further challenges may arise in connection with the manufacture of clinical batches of L-DOS47 or Topical Interferon Alpha-2b which could further delay or otherwise negatively affect the Company's planned IND filings and clinical trials, and the risk of obtaini
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
(Date:2/26/2015)... 2015  23andMe, the leading personal genetics company, today ... Privacy Officer and Corporate Counsel. Black brings a strong ... well as health care regulations. As a member of ... for reviewing, updating and enhancing the company,s privacy and ... She joined the company January 5, 2015 and reports ...
(Date:2/26/2015)... Protiviti ( www.protiviti.com ), a global consulting ... Governance Portal , designed to increase the efficiency with ... across multiple business units and projects. The Governance Portal ... align their controls with the COSO ( Committee of ... response to client feedback, Protiviti has also included a ...
(Date:2/26/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... and hair rejuvenation, has announced that it has ... for investor relations and strategic communications. ... and diversification strategies – and we need to ... stated Ali Kharazmi CEO of NuGene when announcing ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... NOVATO, Calif., June 30 Raptor,Pharmaceuticals Corp. (OTC ... million through a private placement of 20 million ... the Company,s common,stock and two-year warrants to purchase ... agent fees, the Company raised $9.3 million in,net ...
... June 30 SGX Pharmaceuticals,(Nasdaq: SGXP ) ... new,drug (IND) application to the U.S. Food and ... developed, selective, orally-bioavailable,small molecule for the treatment of ... standard of care for CML is Gleevec(R). Although ...
... and get rid of the garbage has sparked allot of attention. ... biosphere units in the Philippines environmental Secretary Jose Atienza warned local ... to shut down open garbage dumps in their jurisdictions. , ... ...
Cached Biology Technology:Raptor Pharmaceuticals Closes $10 Million Private Placement 2Raptor Pharmaceuticals Closes $10 Million Private Placement 3Raptor Pharmaceuticals Closes $10 Million Private Placement 4SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 2SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 3Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale 2Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale 3Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale 4
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... reasons why the world is still plagued by diseases we ... vast complexity of the human immune system. Danish researchers have ... but crucial part of the immune system,s defence mechanisms. This ... Researchers from BioCentrum DTU and the Faculty of Health ...
... An article in the November 2007 issue of BioScience ... of green roofsroofs with a vegetated surface and substrate. ... roof, a green roof can reduce energy costs during ... also provide havens for wildlife. Such structures are currently ...
... change the way we manage the marine environment. New research ... (1 November 2007) in Nature, shows how damaged Caribbean reefs ... Coral reefs conjure up images of rich, colourful ecosystems yet ... by seaweed. The research team wanted to test whether reefs ...
Cached Biology News:Coral reefs will be permanently damaged without urgent action 2
Purified anti-mouse Tim-1...
Request Info...
Request Info...
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Biology Products: